Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Brian Daniel Webster sold 51,900 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total transaction of $1,272,588.00. Following the sale, the insider owned 475,215 shares of the company’s stock, valued at approximately $11,652,271.80. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Brian Daniel Webster also recently made the following trade(s):
- On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total transaction of $311,366.64.
- On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total transaction of $202,224.80.
- On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total transaction of $178,511.04.
- On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00.
- On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.96, for a total value of $314,400.00.
Kestra Medical Technologies Stock Performance
Shares of KMTS opened at $26.40 on Friday. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -10.91 and a beta of 0.58. The business’s fifty day simple moving average is $22.96 and its two-hundred day simple moving average is $22.57. Kestra Medical Technologies, Ltd. has a 12 month low of $14.30 and a 12 month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.
Wall Street Analyst Weigh In
KMTS has been the topic of a number of recent analyst reports. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research boosted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies has an average rating of “Hold” and an average price target of $27.83.
View Our Latest Analysis on KMTS
Institutional Investors Weigh In On Kestra Medical Technologies
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies in the fourth quarter worth approximately $31,000. Russell Investments Group Ltd. raised its position in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. increased its stake in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.
Kestra Medical Technologies Company Profile
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
- Five stocks we like better than Kestra Medical Technologies
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
